Eli Lilly joins up with Camurus to make long-acting versions of the pharma's obesity and diabetes drugs, joining the industry ...

A new report from Pitchbook suggests we’re in for a period of more sustainable investing, with VC firms continuing to create ...

Disappointing results for iluzanebart come shortly after Vigil Neuroscience struck a buy-out deal with Sanofi, but analysts ...

Massachusetts’ life sciences jobs grew by just 0.03% in 2024, according to a new MassBioEd report. Still, the report found ...

Recent decisions to reduce health and science research funding and limit the participation of international students and ...

J&J has a multi-year head start, but Gilead believes it can win market share by delivering a drug with better safety and at ...

Sanofi and BMS paid big money for rare disease and cancer assets, while Regeneron got in the obesity game; AstraZeneca, Gilead and Amgen shone at ASCO; RFK Jr. and the CDC appeared to disagree over ...

Jefferies has predicted more small tuck-in deals to come, as biotechs struggle to access capital despite key clinical ...

The FDA plans to “rapidly make available” rare disease drugs and make use of surrogate endpoints to get promising medicines to patients before they clear the traditional efficacy bar for authorization ...

Kura Oncology won FDA priority review for its drug the day before announcing new data at ASCO 2025 showing remission in about ...

Regeneron’s shares have declined nearly 17% following the failure of the company’s Dupixent follow-up itepekimab.

Analysts said the data suggest “a strong treatment effect.” Jazz has filed for FDA approval for the combination, which could ...